Theravance Biopharma to Present New Data Analyses From Phase 3 ATTAIN Trials of VIBATIV(R) (telavancin) in Treatment of HABP/VABP at American Thoracic Society 2016 International Conference

DUBLIN, IRELAND--(Marketwired - May 11, 2016) - Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that new data on VIBATIV^® (telavancin), the Company's FDA-approved antibiotic, will be the focus of a poster presentation at the American Thoracic Society (ATS) 2016 International Conference. Researchers will present results from post hoc analyses of the previously completed Phase 3 ATTAIN (Assessment of Telavancin for Treatment of Hospital-Acquired Pneumonia) studies, registrational trials which supported the regulatory approval of telavancin (marketed as VIBATIV) for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP). The ATS 2016 International Conference is being held in San Francisco on May 13-18, 2016.

The post hoc analyses were intended to further evaluate and compare the ATTAIN studies' clinical cure rates and safety results for telavancin vs. vancomycin across a range of comorbidities. Findings highlight specific HABP/VABP patient populations, including those with methicillin-resistant Staphylococcus aureus (MRSA), for which VIBATIV may serve as an appropriate treatment. The analyses were conducted by researchers at Weill Cornell Medical Center/Medical College and Baystate Medical Center (Springfield, Mass), in collaboration with Theravance Biopharma. 

Details of the VIBATIV poster presentation are as follows:

Poster #P859: Clinical Efficacy and Safety of Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Patients with Monomicrobial S. aureus Infection  

Viewing Time: Sunday, May 15, 2016, 11:00 a.m. Pacific
Session: Clinical Aspects of CAP, HCAP, HAP, and VAP
Location: Area G, Hall D

VIBATIV is a bactericidal, once-daily, injectable lipoglycopeptide antibiotic with in vitro potency and a dual mechanism of action that both inhibits bacterial cell wall synthesis and disrupts bacterial cell membrane function. The drug's proven efficacy against difficult-to-treat Gram-positive infections has been demonstrated in several large, multinational registrational studies, which involved one of the largest cohorts of patients with S. aureus infections studied to date. Additionally, there is extensive and well-documented evidence of the drug's in vitro potency and in vivo activity against a broad collection of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.